AMRX
Amneal Pharmaceuticals, Inc.
AMRX's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over AMRX overall, supported by stronger fundamentals and stronger modeled upside.
AMRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Under pressure | |
| Unavailable |
AMRX's revenue and profitability are currently healthy, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 13x | $5.39 | -75% |
| Forward | 19x | $21.70 | — |
| Current | 53x | $21.70 | — |
| Fair | 58x | $23.71 | +9.2% |
| Expensive | 616x | $253 | +1064% |
Historical ranges are pointers, not guarantees.
AMRX's PE is in its fair range at 53x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its cheap range.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over AMRX in the historical PE scenario, which offers more potential upside but is not a forecast.
AMRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for AMRX, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
AMRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.14 | +178% |
| Q3 2026 | $0.41 | +1950% |
| Q2 2026 | $0.48 | +4700% |
| Q1 2026 | $0.37 | +$0.41 |
| Q4 2025 | $0.22 | +$0.60 |
| Q3 2025 | $0.02 | +$0.87 |
| Q2 2025 | $0.01 | +$0.80 |
| Q1 2025 | -$0.04 | +$0.69 |
| Q4 2024 | -$0.38 | +$0.10 |
AMRX's earnings per share have fallen from their peak: $0.41 over the past year, against $0.61 in late 2020.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
AMRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $862.7M | +10% |
| Q2 2026 | $796.2M | +9.9% |
| Q1 2026 | $722.5M | +3.9% |
| Q4 2025 | $814.3M | +11% |
| Q3 2025 | $784.5M | +12% |
| Q2 2025 | $724.5M | +3.2% |
| Q1 2025 | $695.4M | +5.5% |
| Q4 2024 | $730.5M | +18% |
AMRX's revenue has grown year over year for 22 quarters in a row: $863M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | +2.1 points |
| Q2 2026 | 16% | +0.9 points |
| Q1 2026 | 20% | +5.2 points |
| Q4 2025 | 14% | +3.4 points |
| Q3 2025 | 9% | -3.7 points |
| Q2 2025 | 15% | +1.8 points |
| Q1 2025 | 14% | +16 points |
| Q4 2024 | 10% | +8.1 points |
AMRX's operating margin was 11% last quarter, up 2.1 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AMRX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over AMRX on profitability, with a higher operating margin.
AMRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $66.5M | -37% |
| Q2 2026 | -$51.9M | -185% |
| Q1 2026 | -$34.9M | -$29.2M |
| Q4 2025 | $108.5M | +5.5% |
| Q3 2025 | $106.2M | -15% |
| Q2 2025 | $61M | +110% |
| Q1 2025 | -$5.8M | +$7.9M |
| Q4 2024 | $102.9M | -18% |
AMRX still generates free cash flow, though less than at its 2020 peak: $88M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over AMRX on cash flow, with more consistent year-over-year improvement.
AMRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.3% | +7.6M shares |
| 1 year | +3.4% | +11M shares |
| 3 years | +117% | +181M shares |
| 5 years | +121% | +184M shares |
| Available history | +154% | +204M shares |
AMRX has 336M diluted shares, up 3.4% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over AMRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AMRX Net Leverage
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
AMRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.8 | Neutral |
| Stochastic | 86.7 | Overbought |
AMRX's weekly RSI is 69 (neutral) and its Stochastic is 87 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AMRX PE vs Healthcare Sector
| Metric | AMRX | Sector median | Relative |
|---|---|---|---|
| PE | 53x | 26x | 105% above |
| PE % | 40 | 29 | 11 pts above |
AMRX is trading at 53x earnings, a 105% premium to the Healthcare sector's median of 26x.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over AMRX on valuation relative to its sector.
AMRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.4 | 6.6% above |
| 20 week MA | $18.8 | 15% above |
| 50 week MA | $15.5 | 40% above |
| 100 week MA | $12.1 | 79% above |
| 200 week MA | $8.62 | 152% above |
AMRX is in an uptrend: it's above all five of its weekly moving averages, and 152% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
AMRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.51 | $4.43 | -1.8% |
| 2021 | $4.43 | $5.07 | +14% |
| 2022 | $5.07 | $2.20 | -57% |
| 2023 | $2.20 | $6.07 | +176% |
| 2024 | $6.07 | $7.82 | +29% |
| 2025 | $7.82 | $13.0 | +66% |
| 2026 YTD | $13.0 | $21.7 | +68% |
AMRX has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.